|
German Federal Joint Committee (G-BA) Issues Final Assessment Report for …
Sacramento Bee The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
|
German Federal Joint Committee (G-BA) Issues Final Assessment Report For …
Daily Markets (press release) The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Making Good Results Even Better: The Evolving Role of Radiotherapy in …Cancer NetworkTwo phase III studies addressed the role of RT in the management of stage I and II DLBCL in the pre-rituximab (Rituxan) era. The SWOG study[1] compared 3 cycles of C…
Gilead Announces Response Data from Phase 2 Study of Idelalisib for …Fort Mills TimesGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, target…
Gilead Announces Response Data from Phase 2 Study of Idelalisib for …MarketWatch (press release)Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigation…
|
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study
Xconomy Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally nailed a new and … Roche Experimental Leukemia Drug Helps Shrink TumorsBloomberg Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease …Wall Street Journal (press release) |
|
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at …
The Herald | HeraldOnline.com The Phase III study CLL11, which is being conducted in close collaboration with the German CLL Study Group (GCLLSG), compared the combination of either GA101 or Rituxan® (rituximab) and standard chemotherapy (chlorambucil) to chlorambucil alone. |
Addition of rituximab to DA-EPOCH negated need for radiotherapy in primary …HealioThe addition of rituximab to dose-adjusted etoposide, doxorubicin, and cyclophosphamide plus vincristine and prednisone prevented the need for radiotherapy in most pati…
 Healthline |
What’s Driving the Surge in Drug Research for “Orphan” Diseases? – Healthline
Healthline For example, Biogen Idec’s drug Rituximab, a breakthrough treatment for B-cell lymphoma, is projected to generate $34 billion in revenue, according to Thomson Reuters. The drug has since proven helpful in treating rheumatoid arthritis, multiple … |
|
Biosimilar drugs’ global revenues “to hit $2.44B this year”
PharmaTimes From 2014, many companies will be trying to launch mAb biosimilar products, and the majority will be targeting Roche’s Rituxan (rituximab) and Herceptin (trastuzumab), and Johnson & Johnson/Merck & Co/Mitsubishi Tanabe’s Remicade (inflximab) for … |